source
- Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapyVaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study. The company is testing a treatm…
- Austria launches up to €100 million anchor investment for growth fund, aiming to channel half‑billion euros into biotechAustria's government announced a new national Startup & Scaleup Fund as part of the 2027/2028 budget, with an anchor investment of up to €100 million. The public money is designed to attract priva…